Drug repurposing against coronavirus disease 2019 (COVID-19): A review
| Autor: | Kaifeng Liu, Lianxiang Luo, Xiaoling Li, Liao Cui, Hui Luo, Qin Qiu, Yuge Huang, Yongqi Lan, Fangfang Huang |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Virtual screening
medicine.medical_specialty Coronavirus disease 2019 (COVID-19) Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Drug repurposing Pharmaceutical Science RM1-950 Pharmacy Disease medicine.disease_cause Article Analytical Chemistry Network pharmacology Drug Discovery Pandemic Electrochemistry medicine Intensive care medicine Spectroscopy Coronavirus SARS-CoV-2 Chemistry COVID-19 Treatment Clinical trial Drug repositioning Therapeutics. Pharmacology 3C-like protease |
| Zdroj: | Journal of Pharmaceutical Analysis, Vol 11, Iss 6, Pp 683-690 (2021) Journal of Pharmaceutical Analysis |
| ISSN: | 2095-1779 |
| DOI: | 10.1016/j.jpha.2021.09.001 |
| Popis: | Since December 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been found to be the culprit in the coronavirus disease (COVID-19), causing a global pandemic. Despite the existence of many vaccine programs, the number of confirmed cases and fatalities due to COVID-19 is still increasing. Furthermore, a number of variants have been reported. Because of the absence of approved anti-coronavirus drugs, the treatment and management of COVID-19 has become a global challenge. Under these circumstances, drug repurposing is an effective method to identify candidate drugs with a shorter cycle of clinical trials. Here, we summarize the current status of the application of drug repurposing in COVID-19, including drug repurposing based on virtual computer screening, network pharmacology, and bioactivity, which may be beneficial COVID-19 treatment. Graphical abstract Image 1 |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|